Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma

Summary

This is an open-label, multi-center Phase I study conducted to define the recommended Phase 2 dose, toxicity profile, pharmacokinetics and biologically active dose range of GSK1059615.

Timeline

Start

2008-06-24

Primary completion

2009-03-31

Completion

2009-03-31

Outcome

Outcome not reported

Stopped: “This study was terminated prematurely due to lack of sufficient exposure following single- and repeat-dosing.”

Drugs

Indications